Robert A. Fenstermaker, M.D.
Chief Medical Officer
Dr. Fenstermaker is a co-inventor of the survivin vaccine technology on which MimiVax was founded. He joined Roswell Park Cancer Institute (RPCI) in 1995, became Chairman of the Department of Neurosurgery in 1997, and was appointed Co-Director of the Gamma Knife Center when it opened in 1998. He earned his medical degree at Northeast Ohio Medical University (previously known as Northeastern Ohio Universities College of Medicine) in 1981. Following residency training in Neurosurgery at University Hospitals of Cleveland in 1986, he completed a fellowship in Pharmacology and Neurological Surgery (1987) and an NIH postdoctoral fellowship in Biochemistry (1989) at Case Western Reserve University School of Medicine in Cleveland, Ohio. Dr. Fenstermaker is licensed to practice medicine in New York and is certified by the American Board of Neurological Surgery (1991). He is also Director of Neurosurgical Oncology and Professor of Neurosurgery at the University at Buffalo School of Medicine and Biomedical Sciences.
Dr. Fenstermaker is a member of the American Association of Neurological Surgeons, Congress of Neurological Surgeons, American College of Surgeons, Society for Neuro-Oncology, Gamma Knife Society, American Association for Cancer Research, and American Medical Association. Currently, he is a member of the CNS Tumor Guidelines Panel of the National Comprehensive Cancer Network. Dr. Fenstermaker has co-authored more than 150 journal articles, book chapters and abstracts. He has been a reviewer for leading cancer and neurosurgical journals and has presented his research at many national and international meetings.
Michael J. Ciesielski, Ph.D.
Chief Scientific Officer
Dr. Ciesielski is a co-inventor of the survivin vaccine technology on which MimiVax was founded. He joined the Academic Faculty of Roswell Park Cancer Institute (RPCI) in 2004 after obtaining his Ph.D. in Immunology from the State University of New York at Buffalo. Prior to this, he established the Neuro-Oncology laboratory together with Dr. Fenstermaker in 1995. Dr. Ciesielski is an Assistant Professor of Neurosurgery and Oncology at Roswell Park Cancer Institute and member of the Graduate Faculty of the University at Buffalo School of Medicine and Biomedical Sciences. He has co-authored more than 42 journal articles and numerous abstracts. He is an active member of the Society for Neuro-Oncology and American Association for Cancer Research and is a reviewer for numerous scientific journals.
Dr. Ciesielski was recently honored with a Research Scholar award from the American Cancer Society. Dr Ciesielski holds 10 global patents, nine of which are for the survivin technology.
Scott E. Friedman, Esq.
Mr. Friedman is a co-founder of MimiVax. In addition to serving as the Company’s General Counsel, he is the Chairman and CEO of Lippes Mathias Wexler Friedman LLP, a Western New York headquartered law firm, which concentrates on representing businesses and entrepreneurs. He co-founded, and sits on the board of, a number of start-up life science companies. Mr. Friedman is experienced in venture capital and private equity transactions and is also a General Partner in Impact Capital, a newly established venture capital fund, and sits on the board of directors of the Western New York Venture Association. Mr. Friedman is the General Editor of a Field Guide for Starting and Growing a Life Science Company in Western New York, a guidebook prepared by the Lippes Mathias law firm and Invest Buffalo Niagara.
Anil K. Goyal, PhD, CLP™
Vice President, Business Development & Strategy
Dr. Goyal brings more than 20 years of experience in deal making, strategic alliances, in/out-licensing, mergers and acquisitions, and strategic planning for private and public therapeutics and diagnostics companies across multiple disease areas, especially immuno-oncology. Most recently, he served as Vice President of Business Development and a member of the management team at Heat Biologics (HTBX) immuno-oncology company. Prior to joining Heat Biologics in 2013, he served as CEO and co-founder of Qualiber, Inc., a cancer nanomedicine company launched at The University of North Carolina at -Chapel Hill. Previous business development leadership roles include: Ascletis Pharmaceuticals (Hangzhou) Pvt. Ltd., Optherion, Inc. and Serenex, Inc. where as VP of Business Development he led the exit/acquisition of Serenex by Pfizer. Earlier in his career, Dr. Goyal held key business and scientific roles at Millennium Pharmaceuticals, Inc. (acquired by Takeda), Genome Therapeutics Corporation, and Merck & Co.
Dr. Goyal received his Ph.D. in Microbiology and Molecular Genetics jointly from Rutgers, The State University and University of Medicine and Dentistry of New Jersey, and is a Certified Licensing Professional (CLP™) by the Licensing Executives Society, Inc.